Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
53 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Rhinovirus Infection - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Rhinovirus Infection - Pipeline Review, H1 2015', provides an overview of the Rhinovirus Infection's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Rhinovirus Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rhinovirus Infection and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Rhinovirus Infection - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Rhinovirus Infection and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Rhinovirus Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Rhinovirus Infection pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Rhinovirus Infection - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Rhinovirus Infection pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Rhinovirus Infection Overview 7 Therapeutics Development 8 Pipeline Products for Rhinovirus Infection - Overview 8 Pipeline Products for Rhinovirus Infection - Comparative Analysis 9 Rhinovirus Infection - Therapeutics under Development by Companies 10 Rhinovirus Infection - Therapeutics under Investigation by Universities/Institutes 12 Rhinovirus Infection - Pipeline Products Glance 13 Clinical Stage Products 13 Early Stage Products 14 Rhinovirus Infection - Products under Development by Companies 15 Rhinovirus Infection - Products under Investigation by Universities/Institutes 16 Rhinovirus Infection - Companies Involved in Therapeutics Development 17 AIMM Therapeutics B.V. 17 Biological Mimetics, Inc. 18 Biota Pharmaceuticals, Inc. 19 Boehringer Ingelheim GmbH 20 Johnson & Johnson 21 Myelo Therapeutics GmbH 22 Theraclone Sciences, Inc. 23 Rhinovirus Infection - Therapeutics Assessment 24 Assessment by Monotherapy Products 24 Assessment by Target 25 Assessment by Mechanism of Action 27 Assessment by Route of Administration 29 Assessment by Molecule Type 31 Drug Profiles 33 KR-22809 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Monoclonal Antibody for Asthma, COPD and Rhinovirus Infections - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Monoclonal Antibody for Human Rhinovirus Infections - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Myelo-001 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 OBR-5340 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 PL-402 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Recombinant Protein for Rhinovirus Infection - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 rhinovirus [serotype 39] vaccine - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Small Molecule for Rhinovirus Infection - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Small Molecules for Rhinovirus Infection - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Small Molecules for Rhinovirus Infections - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Small Molecules to Inhibit RNA Polymerase for Rhinovirus and Picornaviridae Infections - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 vapendavir - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Rhinovirus Infection - Recent Pipeline Updates 48 Rhinovirus Infection - Dormant Projects 50 Rhinovirus Infection - Product Development Milestones 51 Featured News & Press Releases 51 Mar 28, 2012: Biota Announces Positive Phase IIb Data In Asthma Patients With Human Rhinovirus Infection 51 Appendix 52 Methodology 52 Coverage 52 Secondary Research 52 Primary Research 52 Expert Panel Validation 52 Contact Us 52 Disclaimer 53
List of Tables Number of Products under Development for Rhinovirus Infection, H1 2015 8 Number of Products under Development for Rhinovirus Infection - Comparative Analysis, H1 2015 9 Number of Products under Development by Companies, H1 2015 11 Number of Products under Investigation by Universities/Institutes, H1 2015 12 Comparative Analysis by Clinical Stage Development, H1 2015 13 Comparative Analysis by Early Stage Development, H1 2015 14 Products under Development by Companies, H1 2015 15 Products under Investigation by Universities/Institutes, H1 2015 16 Rhinovirus Infection - Pipeline by AIMM Therapeutics B.V., H1 2015 17 Rhinovirus Infection - Pipeline by Biological Mimetics, Inc., H1 2015 18 Rhinovirus Infection - Pipeline by Biota Pharmaceuticals, Inc., H1 2015 19 Rhinovirus Infection - Pipeline by Boehringer Ingelheim GmbH, H1 2015 20 Rhinovirus Infection - Pipeline by Johnson & Johnson, H1 2015 21 Rhinovirus Infection - Pipeline by Myelo Therapeutics GmbH, H1 2015 22 Rhinovirus Infection - Pipeline by Theraclone Sciences, Inc., H1 2015 23 Assessment by Monotherapy Products, H1 2015 24 Number of Products by Stage and Target, H1 2015 26 Number of Products by Stage and Mechanism of Action, H1 2015 28 Number of Products by Stage and Route of Administration, H1 2015 30 Number of Products by Stage and Molecule Type, H1 2015 32 Rhinovirus Infection Therapeutics - Recent Pipeline Updates, H1 2015 48 Rhinovirus Infection - Dormant Projects, H1 2015 50
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
